An interventional study of embolization therapy and embolization followed by aspiration in Hemorrhage, Obstetric, Uterine Abnormality and Uterine Artery Embolization, sponsored by University Hospital, Grenoble. Not yet recruiting at 4 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-03.
Sponsored by University Hospital, Grenoble · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Hemorrhage with a site in France — 25 open to participants now, 31 under way, 4 of them phase 3. Hemorrhage · France.
Among the 120 studies in Hemorrhage with a site in France, this one is the 41st largest by planned enrollment of the 74 interventional ones that give a count, is one of 5 that started in 2026, is one of 35 with no phase, reaches primary completion later than 18 of the 30 other live ones, and was the 116th registered.
1,383 studies on the registry are indexed under Hemorrhage; 244 are open to participants now.
Browse Hemorrhage studies →25 of the 120 studies in Hemorrhage with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Annecy Genevois · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Besancon · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18+
Takeda · Sites in France, United States, Australia and 15 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 170 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 40 (24%) stop at 75 or younger; 25 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 13 · Phase 3 19 · Phase 4 8
First in 2003; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is close to the median of 102 across 926 interventional studies indexed under Hemorrhage.
Median enrollment 150 across the 74 interventional studies, 222 across the 46 observational. Of the 78 that completed or were terminated, 6 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 120 have an industry lead sponsor. The 10 most frequent:
University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.
University Hospital, Grenoble has 5 studies filed under Hemorrhage — fewer than ten, so there is no comparison to draw.
4 of the studies in Hemorrhage with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05198960Phase 3University Hospital, BrestAVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms | 2027-07-13 |
| NCT07259135University Hospital, BordeauxLink Between Abnormal Bleeding and Coagulation Disorders in Noonan Syndromes | 2027-01 |
| NCT06425614University Hospital, BordeauxCOmbined pLaTelet and eRythrocyte AutotransfusioN During Cardiac surgEry (COLTRANE) Trial | 2027-02-15 |
| NCT06749405University Hospital, ToulouseAssessment of a Quantra-guided Transfusion Algorithm in Liver Transplantation | 2027-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 120 studies in Hemorrhage with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine the best treatment for patients who experience vaginal bleeding following a premature termination of pregnancy.
The main questions it aims to answer are:
The researchers will evaluate the patients over a period of 12 months.
Participants will:
Ten to 15% of pregnancies end in the first trimester. Voluntary termination of pregnancy and spontaneous miscarriage, the two main causes of pregnancy loss, are managed medically or surgically in order to remove the intrauterine residue and restore a vacant uterus. In cases of incomplete evacuation, uterine retention may persist in approximately 1% of all pregnancies and up to 40% of pregnancy terminations in the second trimester.
The management of uterine retention depends on the clinical presentation and its vascularization on ultrasound. If it is not vascularized or only slightly vascularized, simple aspiration or monitoring is considered. In cases of hypervascularity, treatment is debated given the variable amount of bleeding and the sometimes spontaneously favorable outcome. Doppler criteria (systolic peak velocity, resistance index, or vascular invasion of the myometrium) have been described to select patients who are likely to have a spontaneous favorable outcome from those who require invasive management. In cases of hypervascularized intrauterine retention with negative findings on Doppler ultrasound, performing endometrial aspiration carries a significant risk of severe bleeding during the procedure and is generally preceded by embolization in order to minimize this risk (embolization + aspiration). Aspiration induces adhesions (synechiae) that can impair the patient's future fertility.
Recent publications show the effectiveness of temporary embolization alone using resorbable gelatin fragments to stop bleeding. Our team has reported uterine emptiness rates of approximately 75% at 1 month and 95% at 3 months after embolization alone with resorbable gelatin.
The objective of this study is therefore to evaluate the non-inferiority of embolization alone with resorbable gelatin compared to embolization followed by endometrial aspiration in patients with hypervascularized and hemorrhagic intrauterine retention following premature termination of pregnancy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo embolization alone, which involves temporarily blocking the uterine artery or arteries supplying a hypervascular abnormality using resorbable gelatin fragments.
Procedure: embolization therapy
Patients will undergo embolization prior to endometrial aspiration. Embolization will be performed in the same manner as in group "Embolization alone" but will be followed within 48 hours by a second procedure to remove the intrauterine residue that will have been devascularized (= deprived of blood) by the embolization.
Procedure: embolization followed by aspiration
Patients will undergo embolization alone, which involves temporarily blocking the uterine artery or arteries supplying a hypervascular abnormality using resorbable gelatin fragments.
Also known as: embolic agent
Patients will undergo embolization prior to endometrial aspiration. Embolization will be performed in the same manner as in group "Embolization alone" but will be followed within 48 hours by a second procedure to remove the intrauterine residue that will have been devascularized (= deprived of blood) by the embolization.
Also known as: endometrial aspiration, intrauterine aspiration, hysteroscopy
Clinical success post-procedure as assessed by Doppler-ultrasound
The primary endpoint is clinical success defined by a null uterine cavity on follow-up Doppler ultrasound and no persistent or recurrent bleeding requiring a new procedure
Time frame: From baseline to 3 months after procedure
Persistence or recurrence of bleeding at 1 month follow-up in both groups.
Evaluate the effectiveness of embolization alone versus embolization followed by aspiration at 1 month of follow-up in stopping bleeding in patients with hypervascularized hemorrhagic uterine retention following premature termination of pregnancy.
Time frame: From baseline to 1 month
Safety of both treatments
Complications attributable to procedures within 90 days of admission according to the Clavien-Dindo classification
Time frame: Fom intervention to 90 days after
the effectiveness of embolization alone compared to embolization followed by uterine evacuation at 1 month after procedure
Measurement of uterine emptiness on Doppler ultrasound at 1 month
Time frame: From intervention to 1 month
the effectiveness of embolization alone compared to embolization followed by uterine evacuation at 3 months after procedure
Measurement of uterine emptiness on Doppler ultrasound at 3 months
Time frame: From intervention to 3 months
the impact of embolization alone compared to embolization followed by aspiration on the resumption of the menstrual cycle
Time between intervention and resumption of menstrual cycle
Time frame: From intervention to 12 months
the impact of embolization alone versus embolization followed by aspiration on subsequent fertility
New pregnancy occurring within 12 months of the patient's admission
Time frame: From intervention to 12 months
If infertility diagnosis within 12 months, the rate of synechiae found between the two groups.
Uterine adhesions on hysteroscopy performed for infertility assessment.
Time frame: From intervention to 12 months
Plan to share: No
Start is estimated for Jan 2026; primary completion for Mar 2028, 26 months later.
Of 192 non-industry interventional studies with no phase under Hemorrhage, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 26 months is above that.
Counting every sponsor, half of 227 studies reached it within 19 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble →